Theralase Technologies Inc (TLTFF)

[123414]

Potential Drive to .45 USD

Price calculated from trendline monthly chart Plots and company's latest phase 2 study CR rates:

Highs for August 2017
April 2019.

Expectation:

Market response similar to Monthly Chart period Nov 2016 through Aug 2017.



This current price level on the Ten-year Month,
is a historical point where sometimes the company sp really jumps up from these levels. Provided the company is making progress in their business plans. And they are.

if you consider the range the stock has held for so many years that is well above the current price point.

You might consider the market assessed the stock to be worth the SP at that time. And this was before they were approved for a Phase 2 study and before they had the data points that are unprecedented.

Before PHAC and St. Michaels.

So for me I see the value.

_________________________________________________

The hard and long fall from March 2019.

At the closing of the phase one study buyers were looking for the next business development and it was a long way out. The price fall began in March. Other investors soon realized how far out the next significant steps would be taken for Phase 2 Pivotal. And the market forces propelled.

The market forces are again propelling in the opposite.

______________________________________________________

TORONTO, ON / ACCESSWIRE / January 31, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment.

The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints.

Patient five has demonstrated no tumour recurrence or presence of disease at the 90, 180, 270 and now 360 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company.

Patients five and six were enrolled and treated in the Study at the Therapeutic Dose (0.70 mg/cm2). Theralase's Anti-Cancer Treatment involved the intravesical instillation of a water-based solution of Theralase's lead anti-cancer PDC, TLD-1433, via a catheter inserted through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours. The bladder was then drained of the solution, flushed with sterile water to remove non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, comprising a Laser Emitter used to emit laser light and a proprietary Dosimetry System used to detect laser light, were then used to activate TLD-1433 resident in the NMIBC tumours.
------------------------------------------------

Monthly Chart Nov 2019 to present
Large down gaps, monthly chart 2019 July & August
Large up gaps, monthly chart 2021 Nov & Dec



2019 July Monthly High .3920 Low .2370
2019 August Monthly High .2609 Low .1636
2019 August Monthly gap filled - 2021 November
2021 November Monthly Low .1366 High . 2206

July 2019 Monthly Down gap fill in progress - Dec 2021.
2021 December Monthly Low .1950 High . 2989
Current .259

----------------------------------------------


https://theralase.com/theralase-releases-3q21-financial-statements-and-newsletter/

Study II Preliminary Results
As of November 29, 2021, Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients, demonstrating the following interim results:

Note: Significant clinical data is still pending in Study II and drawing conclusions from this interim clinical data set and assumptions should be done with caution, as Study II is still ongoing and new clinical data collected may or may not continue to support the current trend.


*Includes three (3) patients treated at the Therapeutic Dose form Phase Ib NMIBC Clinical Study (2-CR and 1- NR at 90, 180, 270, 360, 450 days)

An analysis of the Study II clinical data (with 3 patients from Study Ib) provides the following interim assessments:

7/10 patients (70.0%), who achieved a CR at 90 days continue to demonstrate CR at 180 days
In the total population of 33 patients (@ 90 days):
42.4% achieved Complete Response (“CR”)
12.1% achieved Partial Response (“PR”)
21.2% are Pending
24.2% achieved No Response (“NR”)
Hence, the potential for CR is up to 75.8%** for the interim clinical data analysis.

Note**: Assumes both PR and Pending data are clinically determined to be CR at a later assessment date.

In the total population of 18 patients (@ 90 days), who received the optimized treatment:
44.4% achieved CR
11.1% achieved PR
38.9% are Pending
5.6% achieved NR
Hence, the potential for CR is up to 94.4%***